Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation
Standard
Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. / Kelly, Debra Lynch; Buchbinder, David; Duarte, Rafael F; Auletta, Jeffrey J; Bhatt, Neel; Byrne, Michael; DeFilipp, Zachariah; Gabriel, Melissa; Mahindra, Anuj; Norkin, Maxim; Schoemans, Helene; Shah, Ami J; Ahmed, Ibrahim; Atsuta, Yoshiko; Basak, Grzegorz W; Beattie, Sara; Bhella, Sita; Bredeson, Christopher; Bunin, Nancy; Dalal, Jignesh; Daly, Andrew; Gajewski, James; Gale, Robert Peter; Galvin, John; Hamadani, Mehdi; Hayashi, Robert J; Adekola, Kehinde; Law, Jason; Lee, Catherine J; Liesveld, Jane; Malone, Adriana K; Nagler, Arnon; Naik, Seema; Nishihori, Taiga; Parsons, Susan K; Scherwath, Angela; Schofield, Hannah-Lise; Soiffer, Robert; Szer, Jeff; Twist, Ida; Warwick, Anne; Wirk, Baldeep M; Yi, Jean; Battiwalla, Minoo; Flowers, Mary E; Savani, Bipin; Shaw, Bronwen E.
In: BIOL BLOOD MARROW TR, Vol. 24, No. 2, 02.2018, p. 228-241.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation
AU - Kelly, Debra Lynch
AU - Buchbinder, David
AU - Duarte, Rafael F
AU - Auletta, Jeffrey J
AU - Bhatt, Neel
AU - Byrne, Michael
AU - DeFilipp, Zachariah
AU - Gabriel, Melissa
AU - Mahindra, Anuj
AU - Norkin, Maxim
AU - Schoemans, Helene
AU - Shah, Ami J
AU - Ahmed, Ibrahim
AU - Atsuta, Yoshiko
AU - Basak, Grzegorz W
AU - Beattie, Sara
AU - Bhella, Sita
AU - Bredeson, Christopher
AU - Bunin, Nancy
AU - Dalal, Jignesh
AU - Daly, Andrew
AU - Gajewski, James
AU - Gale, Robert Peter
AU - Galvin, John
AU - Hamadani, Mehdi
AU - Hayashi, Robert J
AU - Adekola, Kehinde
AU - Law, Jason
AU - Lee, Catherine J
AU - Liesveld, Jane
AU - Malone, Adriana K
AU - Nagler, Arnon
AU - Naik, Seema
AU - Nishihori, Taiga
AU - Parsons, Susan K
AU - Scherwath, Angela
AU - Schofield, Hannah-Lise
AU - Soiffer, Robert
AU - Szer, Jeff
AU - Twist, Ida
AU - Warwick, Anne
AU - Wirk, Baldeep M
AU - Yi, Jean
AU - Battiwalla, Minoo
AU - Flowers, Mary E
AU - Savani, Bipin
AU - Shaw, Bronwen E
N1 - Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
PY - 2018/2
Y1 - 2018/2
N2 - Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT. In this review we define what constitutes neurocognitive dysfunction, characterize its risk factors and sequelae, describe tools and methods to assess neurocognitive function in HCT recipients, and discuss possible interventions for HCT patients with this condition. This review aims to help clinicians understand the scope of this health-related problem, highlight its impact on well-being of survivors, and help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT. In particular, we review strategies for preventing and treating neurocognitive dysfunction in HCT patients. Finally, we highlight the need for well-designed studies to develop and test interventions aimed at preventing and improving neurocognitive dysfunction and its sequelae after HCT.
AB - Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT. In this review we define what constitutes neurocognitive dysfunction, characterize its risk factors and sequelae, describe tools and methods to assess neurocognitive function in HCT recipients, and discuss possible interventions for HCT patients with this condition. This review aims to help clinicians understand the scope of this health-related problem, highlight its impact on well-being of survivors, and help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT. In particular, we review strategies for preventing and treating neurocognitive dysfunction in HCT patients. Finally, we highlight the need for well-designed studies to develop and test interventions aimed at preventing and improving neurocognitive dysfunction and its sequelae after HCT.
KW - Journal Article
KW - Review
U2 - 10.1016/j.bbmt.2017.09.004
DO - 10.1016/j.bbmt.2017.09.004
M3 - SCORING: Review article
C2 - 28939455
VL - 24
SP - 228
EP - 241
JO - BIOL BLOOD MARROW TR
JF - BIOL BLOOD MARROW TR
SN - 1083-8791
IS - 2
ER -